Dasaren
Generic Name
dasaren-140-mg-tablet
Manufacturer
Hypothetical Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| dasaren 140 mg tablet | ৳ 550.00 | ৳ 2,750.00 |
Description
Overview of the medicine
Dasaren 140 mg Tablet contains Dasaren, a novel direct-acting antiviral medication designed for the treatment of certain chronic viral infections in adults, often used in combination therapy to achieve a sustained virologic response.
Uses & Indications
Dosage
Adults
140 mg orally once daily, in combination with other prescribed antiviral agents, for a duration determined by the physician (e.g., 8-12 weeks).
Elderly
No dosage adjustment is required based on age alone. However, renal and hepatic function should be monitored.
Renal_impairment
For mild to moderate renal impairment, no dose adjustment is necessary. For severe renal impairment (eGFR < 30 mL/min) or end-stage renal disease, a reduced dose of 70 mg once daily may be considered with careful monitoring.
How to Take
Take Dasaren 140 mg tablet orally once daily, with or without food. The tablet should be swallowed whole and not chewed, crushed, or broken.
Mechanism of Action
Dasaren acts as a highly selective inhibitor of a key viral protein (e.g., NS5A or NS5B analogue for a hypothetical virus), crucial for viral replication and assembly. By binding to this protein, Dasaren disrupts the viral life cycle, thereby reducing viral load.
Pharmacokinetics
Onset
Significant reduction in viral load observed within the first few days of treatment.
Excretion
Mainly excreted via the fecal route (approximately 70-80%), with a smaller proportion eliminated renally.
Half life
Approximately 18-24 hours, supporting once-daily dosing.
Absorption
Rapidly absorbed after oral administration, reaching peak plasma concentrations within 1-3 hours. Bioavailability is high.
Metabolism
Primarily metabolized in the liver by cytochrome P450 3A (CYP3A) enzymes, with minimal active metabolites.
Side Effects
Contraindications
- Hypersensitivity to Dasaren or any component of the tablet.
- Co-administration with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine, St. John's wort) due to potential for significant reduction in Dasaren plasma levels, leading to loss of therapeutic effect.
Drug Interactions
Moderate CYP3A inducers (e.g., efavirenz, etravirine)
May decrease Dasaren plasma concentrations, potentially requiring a dose increase of Dasaren or alternative antiviral therapy.
Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin)
May significantly increase Dasaren plasma concentrations, potentially requiring a dose reduction of Dasaren.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of the sight and reach of children.
Overdose
In case of overdose, no specific antidote is available. Treatment should consist of general supportive measures, including monitoring of vital signs and observation of the patient's clinical status. Due to high protein binding, hemodialysis is unlikely to remove significant amounts of Dasaren from the body.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus. However, there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown whether Dasaren is excreted in human milk; caution should be exercised when administered to a nursing woman.
Side Effects
Contraindications
- Hypersensitivity to Dasaren or any component of the tablet.
- Co-administration with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine, St. John's wort) due to potential for significant reduction in Dasaren plasma levels, leading to loss of therapeutic effect.
Drug Interactions
Moderate CYP3A inducers (e.g., efavirenz, etravirine)
May decrease Dasaren plasma concentrations, potentially requiring a dose increase of Dasaren or alternative antiviral therapy.
Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin)
May significantly increase Dasaren plasma concentrations, potentially requiring a dose reduction of Dasaren.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of the sight and reach of children.
Overdose
In case of overdose, no specific antidote is available. Treatment should consist of general supportive measures, including monitoring of vital signs and observation of the patient's clinical status. Due to high protein binding, hemodialysis is unlikely to remove significant amounts of Dasaren from the body.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus. However, there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown whether Dasaren is excreted in human milk; caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from the date of manufacture.
Availability
Pharmacies, Hospitals
Approval Status
Approved (Hypothetical)
Patent Status
Patent Pending
Clinical Trials
Dasaren has undergone comprehensive Phase I, II, and III clinical trials involving a large cohort of patients with chronic viral infections. These studies demonstrated its safety, efficacy, and ability to achieve high rates of sustained virologic response when used in combination regimens.
Lab Monitoring
- Baseline and periodic liver function tests (ALT, AST, bilirubin).
- Baseline and periodic renal function tests (creatinine, eGFR).
- Viral load (e.g., HCV RNA or equivalent) monitoring to assess treatment response at weeks 4, 12, and 24 post-treatment.
Doctor Notes
- Educate patients on the importance of adherence to the full treatment course.
- Monitor for potential drug-drug interactions, especially with CYP3A modulators.
- Regularly assess liver function and viral load to confirm treatment efficacy and safety.
Patient Guidelines
- Take Dasaren exactly as prescribed; do not alter the dose or stop treatment without consulting your doctor.
- Inform your healthcare provider about all medications, herbal products, and supplements you are taking to avoid potential drug interactions.
- Report any new or worsening symptoms, especially signs of liver problems (e.g., yellowing of skin/eyes, dark urine, severe fatigue).
Missed Dose Advice
If a dose is missed within 12 hours of the scheduled time, take it as soon as possible. If more than 12 hours have passed, skip the missed dose and take the next dose at the regular scheduled time. Do not take a double dose to make up for a missed one.
Driving Precautions
Dasaren may cause side effects like headache, fatigue, or dizziness, which could impair your ability to drive or operate machinery. Exercise caution and avoid such activities if you experience these symptoms.
Lifestyle Advice
- Maintain a healthy and balanced diet.
- Avoid alcohol consumption during treatment, as it can exacerbate liver conditions.
- Regular exercise may help improve overall well-being.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Dasaren Brand
Other medicines available under the same brand name
